TGFBR2 and invasive carcinoma: Importantly, the extent of co-expression of these receptors in invasive carcinomas significantly declined to only 29.5% for PRLR/TGFβR1 (p = 0.02) and 28.12% for PRLR/TGFβR2 (p = 0.049) (Table 1, Figure 1).